Supplementary Information from Blockade of Myeloid-Derived Suppressor Cell Expansion with All-<i>Trans</i> Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy

Abstract

&lt;p&gt;The file Supplementary Information contains 9 Supplementary Figures and additional Materials and Methods mainly related to experiments done during the process of the Revision. Here is a short description of each Supplementary Figure: Supplementary Figure S1. Reduction of the DC101 dosage to 10 mg/kg results in a significant, additive treatment effect in the TS/A model when combined with ATRA. Supplementary Figure S2. Growth curves showing tumor kinetics up to 9 days after stopping the treatment with DC101 and ATRA. Supplementary Figure S3. ATRA decreases the DC101-induced expression of the alternative hypoxia marker GLUT1, whereas CD8+ T-cell and NK cell populations in TS/A breast cancer tumors remain unchanged upon treatment. Supplementary Figure S4. Characterization of the proangiogenic phenotype of tumor-infiltrating MDSC. Supplementary Figure S5. Characterization of the matricellular composition in 4T1 tumors. Supplementary Figure S6. In vitro generated MDSC efficiently suppress T cell proliferation. Supplementary Figure S7. (A) Intratumoral S100A8 levels show a strong correlation with FITC-lectin leakage. (B) ATRA has no direct influence on ZO-1 protein levels in vitro. Supplementary Figure S8. The therapeutic efficiency of DC101 is not increased in S100A9 knockout bone marrow transplanted mice, which exhibit tumor-dependent S100A8 recovery. Supplementary Figure S9. Analysis of the Vegf and Fgf expression levels of mast cells and cancer associated fibroblasts in 4T1 tumors. The Supplementary Materials and Methods section contains a description of: used Reagents and proteins, quantitative PCR, sequences of oligonucleotide primers used for quantitative PCR, fluorescence activated cell sorting (FACS) of mast cells and cancer assoicated fibroblasts, bone marrow transplantation, scanning electron microscopy, western blotting, ELISA, allogeneic T cell proliferation assay, metabolomic analysis of 4T1 tumor tissue.&lt;/p&gt;